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Abstract 
In this study, we constructed multifunctional liposomes with preferentially mitochondria-targeted feature and gold 
nanoparticles-assisted synergistic photodynamic therapy. We systemically investigated the in vitro X-ray triggered PDT 
effect of these liposomes on HCT 116 cells including the levels of singlet oxygen, mitochondrial membrane potential, 
cell apoptosis/necrosis and the expression of apoptosis-related proteins. The results corroborated that synchronous 
action of PDT and X-ray radiation enhance the generation of cytotoxic reactive oxygen species produced from the 
engineered liposomes, causing mitochondrial dysfunction and increasing the levels of apoptosis.
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Background
Photodynamic therapy (PDT) is a noninvasive therapy 
which has been widely used for cancer treatment [1, 2]. In 
this approach, a PDT drug (referred to as photosensitiser) 
is administered and subsequently activated by illumina-
tion with visible light at the target site. The activated pho-
tosensitiser reacts with available oxygen to form reactive 
oxygen species (ROS), which induce tumour cell death 
and vascular shutdown. The therapeutic effect of PDT 
depends on generation of sufficient amounts of ROS. Sin-
glet oxygen (1O2), as one of the primary cytotoxic ROS, is 
generated by energy transfer between the triplet excited 
state of photosensitizers and the ground state of  O2 [3]. 
Since the generated 1O2 has a short lifetime (~ 40  ns) 
and diffusion radius (~ 20  nm), it would be desirable 
for a PDT drug to be located in an organelle that sensi-
tively responds to toxic effects of 1O2 [4–7]. Among the 
organelles of mammalian cells, mitochondria (~ 900 nm 
wide) were intensively studied as a target site of 1O2 to 
enhance PDT effect since they are highly susceptible to 
oxidative damage induced by 1O2 [8–12]. Targeted deliv-
ery of 1O2 induces dysfunction of mitochondria, leading 
to apoptotic death of cancer cells [13, 14].
Because of the negative membrane potential of the 
mitochondrial inner membrane, the mitochondria tar-
geting approaches used earlier were based on the conju-
gation of lipophilic cations to the drugs or drug delivery 
vehicles [15]. Representative cations that are capable of 
mitochondria targeting include guanidinium, bisguani-
dinium and triphenylphosphine (TPP) [16–18]. Due 
to the advantages of TPP and its derivatives over other 
targeting moieties (stability in biological systems, simul-
taneous lipophilic and hydrophilic properties, and the 
absence of light absorption or fluorescence in the vis-
ible or near-infrared spectral region) [19, 20], the TPP 
moiety has been frequently used for directing chemo-
therapeutics, imaging probes and photosensitizers to the 
 mitochondria[ [21–23].
The utility of PDT in the clinic have been hampered 
by the difficulty in delivering sufficient light to deep 
tumours. For example, red light (620–750 nm) required 
Open Access
Journal of Nanobiotechnology
*Correspondence:  e.goldys@unsw.edu.au; wei.deng@unsw.edu.au
†Ewa M. Goldys and Wei Deng are equal senior authors
2 ARC Centre of Excellence for Nanoscale Biophotonics, Graduate School 
of Biomedical Engineering, University of New South Wales, Kensington, 
NSW 2052, Australia
Full list of author information is available at the end of the article
Page 2 of 13Gu et al. J Nanobiotechnol           (2020) 18:87 
to activate verteporfin (VP, a PDT drug) penetrates only 
up to 3 mm allowing to treat superficial lesions only. The 
X-ray-induced PDT has emerged as an attractive alterna-
tive as it is able to overcome limited penetration depth 
of activating light in traditional PDT [24–28]. Unlike vis-
ible or near-infrared (NIR) light, X-rays have excellent 
tissue penetration capability. This emerging approach 
can potentially expand the scope of PDT in clinical appli-
cations. The X-ray induced PDT also offers an innova-
tive feature of precise synchronisation of radiation and 
PDT, which are both cytotoxic but via different mecha-
nisms, offering opportunities for synergistic effects and 
enhanced therapeutic efficacy. As cytotoxic species can 
only be generated within the radiotherapy field, any tox-
icity to other healthy tissues is largely reduced [29].
Earlier studies in the area of X-PDT employed scintil-
lating nanoparticles to convert X-ray photons to visible 
photons, activating a nearby photosensitiser to produce 
ROS [26, 30, 31]. By contrast, our group established 
that verteporfin can be directly activated by low dose 
X-ray radiation, which we utilised in X-ray triggered 
drug release and X-ray induced PDT [24, 32]. The X-ray-
induced ROS generation from verteporfin is caused by 
energetic secondary electrons produced in the tissue 
during X-ray radiation and a contribution from photo-
excitation by Cherenkov radiation [32]. Compared with 
scintillator-mediated X-ray PDT, our approach to X-PDT 
relies on clinically approved agents such as verteporfin 
and this will aid and accelerate clinical translation. Due 
to the hydrophobicity of verteporfin, it requires formu-
lation within liposomes to be clinically applicable [33]. 
Our liposome formulation is specifically designed for 
verteporfin activation from X-ray triggering [24]. Table 1 
compares different attributes of our liposome formula-
tion, with published approaches to comparable trigger-
able liposomes [34–36] providing evidence of novelty of 
this work.
In this report we describe rationally designed mito-
chondria-targeted liposomes that carry and direct 
verteporfin to the mitochondria where a low dose X-ray 
radiation is able to trigger generation of cytotoxic 1O2 
from verteporfin. Co-encapsulation of gold nanoparticles 
(10 nm) in the central core of the liposomes enhances 1O2 
generation. Scheme  1 illustrates the formulation of the 
liposome system and the mechanism of mitochondria-
targeted PDT. Subcellular localization of the liposomes, 
intracellular 1O2 generation, changes in mitochondrial 
membrane potential (Δψm), cellular apoptosis/necrosis 
pathway and in vitro X-ray triggered PDT effect in human 




salt) (DOTAP) (Catalogue No. 890890), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) (Catalogue No. 
850375), 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[amino(polyethylene glycol)-2000] (ammo-
nium salt) (DSPE-PEG(2000)-NH2) (Catalogue No. 
880128), chloroform (Catalogue No. C2432), verteporfin 
(Catalogue No. SML0534), dimethyl sulfoxide (DMSO) 
(Catalogue No. 472301), 10  nm Gold nanoparticles 
(Catalogue No. 752584), 5 nm Gold nanoparticles (Cata-
logue No. 752568), (4-Carboxybutyl)triphenylphospho-
nium bromide (TPP-COOH) (Catalogue No. 157945), 
N-Hydroxysuccinimide (NHS) (Catalogue No. 130672), 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) (Catalogue No. E7750), McCoy’s 
5A Medium (Catalogue No. M8403), 2-(N-Morpholino) 
ethanesulfonic acid (MES) (Catalogue No. M3671), 
Methanol (Catalogue No. 34860) were purchased from 
Sigma-Aldrich Pty Ltd. Singlet Oxygen Sensor Green 
(SOSG) (Catalogue No. S36002), Fetal Bovine Serum 
(FBS) (Catalogue No. 16000036), live cell imaging solu-
tion (Catalogue No. A14291DJ), NucblueTM live cell 
stain readyprobesTM reagent (Catalogue No. R37605), 
MitoTracker™ deep red FM (Catalogue No. M 22426), 
LysoTracker™ Red DND-99 (Catalogue No. L7528), Dul-
becco’s Phosphate-Buffered Saline (DPBS) (Catalogue 
No. 14190144), RIPA Lysis and Extraction Buffer (Cata-
logue No. 89900), Halt™ Protease Inhibitor Cocktail 
(100X) (Catalogue No. 78438), PVDF Pre-cut Blotting 
Table 1 Features of our liposomes v.s. other triggered liposome formulations
Attribute This work Ref. [34] Ref. [35] Ref. [36]
Liposome has one photosensitizer inside + + + +
Gold nanomaterials in the bilayer or the middle core + – – –
Liposome is destabilised (triggered) by ROS generated in the liposome + + + +
Liposome is destabilised (triggered) by ROS generated from radiation X-ray 
radiation
+ – – –
Free of chemodrug toxicity + – – –
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Membranes (Catalogue No. LC2002), Blocker™ BSA 
(10X) in TBS (Catalogue No. 37520), NuPAGE™ 10% 
Bis–Tris Protein Gels (Catalogue No. NP0315BOX), 
Pierce™ 20X TBS Tween™ 20 Buffer (TBST, Cat No. 
28360) and Pierce™ ECL Western Blotting Substrate (Cat 
No. 32109) were purchased from Thermo Fisher Scien-
tific Inc. Cleaved Caspase-3 (Asp175) Rabbit mAb (Bioti-
nylated) (Cat No. 9654S, Bax Antibody (Cat No. 2774S), 
Bad (D24A9) Rabbit mAb (Cat No. 9239S), Streptavidin-
HRP (3999S) and Anti-rabbit IgG, HRP-linked Antibody 
Scheme 1 The schematic illustration of a the liposome formulation and b mitochondria-targeted X-ray induced PDT via the liposome delivery 
system
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(7074S) were purchased from Cell Signalling Technol-
ogy. Apoptosis/necrosis/healthy detection kit (Catalogue 
No. PK-CA707-30018) and CellTiter  96® AQueous one 
solution cell proliferation assay (Catalogue No. G3582) 
were purchased from Promega Corporation.JC-1-mi-
tochondrial membrane potential assay kit (Catalogue 
No. ab113850) was purchased from Abcam Corpora-
tion. Eagle’s Minimum Essential Medium (Catalogue No. 
ATCC ®30-2003) was purchased from ATCC.
Methods
Preparation of pure liposomes and liposomes 
incorporating gold nanoparticles and VP
Liposome-based nanocarriers in this work were prepared 
using a thin-film hydration method [24]. Briefly, 25  µL 
of DOTAP (100  mM) was mixed with 25  µL of DOPC 
(100 mM) dissolved in chloroform, followed by addition 
of 4 µL VP solution (3 mM, dissolved in DMSO). For the 
synthesis of pure liposomes and liposomes loaded with 
gold nanoparticles alone, VP were omitted in the mix-
ture solution. The mixture solvent was then evaporated 
in a rotary evaporator  (Rotavapor® R-300, BÜCHI) for 
10 min at 70  °C. The thin lipid film was formed around 
the wall of the flask and subsequently hydrated with 
PBS buffer (pH 7.4) (in the case of pure liposomes and 
liposomes incorporating VP only) or gold nanoparticle 
suspension (in the case of liposomes incorporating VP 
and gold nanoparticles) with vigorous stirring for 30 min 
until the suspension was homogenized (Vortexer, Heath-
row Scientific). The hydrated lipid suspension was kept at 
room temperature for 3 h to allow the maximal swelling 
of liposomes. The suspension was then extruded eleven 
times through a 200 nm polycarbonate membrane in an 
automated extrusion equipment (NanoSizerTM AUTO, 
T&T Scientific Corporation, USA). The resultant suspen-
sion was stored at 4 °C.
Liposome surface modification with TPP‑COOH
PEGylated and TPP-conjugated liposomes were prepared 
by post-insertion of DSPE-PEG(2000)-NH2 micelles 
into preformed liposomes and subsequent EDC-NHS 
coupling method with slight modifications [37]. In 
brief, 500 μL of aforementioned liposomes and 50 μL of 
DSPE-PEG(2000)-NH2 (0.01  M in distilled water) co-
incubated at 60  °C for 1 h, followed by centrifugation 3 
times (10,000  rpm, 10  min) with Amicon Ultra 0.5  mL 
centrifugal filters (100 kDa) to remove the free molecules. 
After that TPP-COOH (10  mg) was dissolved in 1  mL 
MES buffer (pH = 6), followed by addition of a mixture of 
EDC and NHS (molar ratio, 1:1). The solution was kept at 
room temperature for 30 min under stirring. After raising 
pH to 7.0–7.4, 200 µL of prepared PEGylated liposome 
suspension was added into the activated TPP solution. 
The mixed solution was gently vibrated via orbital shaker 
for 4 h at room temperature. After reaction, the solution 
was washed with PBS buffer three times (11,000  rpm, 
10  min each time) with Amicon Ultra centrifugal filters 
(100 kDa). The final liposome conjugate suspension was 
kept at 4 °C for future use.
Characterisation of liposomes
The extinction spectra of pure gold colloidal solution 
and prepared liposome samples were measured using 
a spectrophotometer (Cary 5000 UV–Vis-NIR, Agi-
lent Technologies). Size distribution and zeta potentials 
of liposomes were measured under a Zetasizer Nano-
ZS from Malvern Panalytical Co. The morphology of 
liposomes was determined using Transmission Electron 
Microscopy (TEM). For TEM imaging, the liposome 
samples were prepared by placing a drop of suspension 
onto a copper grid and air dried, following negative stain-
ing for contrast enhancement. The air-dried samples 
were then imaged by a PHILIPS CM 10 system at an 
accelerating voltage of 100 kV. Images were captured with 
an Olympus Megaview G10 camera and iTEM software.
Assessment of 1O2 generation from the liposome samples 
under X‑ray radiation
1O2 generation was detected by using SOSG probe based 
on our previous work 1.8 µL of SOSG (500  μM) was 
mixed with 200 µL of liposome suspension, followed by 
X-ray radiation at different dosage (1 Gy, 2 Gy and 4 Gy). 
The irradiation of samples was carried out via a 320 kV 
cabinet X-Ray Irradiator (X-RAD 320, Precision X-Ray, 
Inc.). The fluorescence signal of SOSG (excitation/emis-
sion wavelength: 488/525  nm) was recorded before and 
after X-ray radiation in a spectrofluorometer (Fluoro-
Max-4 HORIBA Scientific Co.)
Cell culture and X‑ray radiation on cells
Human colon adenocarcinoma (HCT116 cells) and nor-
mal human colon epithelial cells (CCD841 CoN) were 
purchased from the American Type Culture Collection. 
HCT116 cells were cultured in McCoy’s 5 A (modi-
fied) medium and CCD841 CoN cells were cultured in 
EMEM. All culture media were supplemented with 10% 
FBS and 1% antibiotic–antimycotic. The flasks were incu-
bated at 37 °C in the presence of 5%  CO2 humidified air. 
The cells were seeded at appropriate dilutions into glass-
bottom petri dishes for cell imaging or 96-well plates for 
cell viability assays. For X-ray radiation experiments, the 
cells were radiated by using the same X-ray irradiator as 
described in the 1O2 generation assessment.
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Imaging and analysis of cellular uptake of the liposomes
HCT116 cells (3 × 104 cells/mL) were seeded in glass-
bottom petri dishes and incubated at 37  °C for 48  h 
before treatment with the liposome suspension. After 
removing the culture medium, the cells were incubated 
with the liposome suspension (250 µM) in culture media 
for 1 h, 2 h and 4 h. The cells were then washed with PBS 
buffer (pH 7.4) three times to remove free liposomes. To 
assess the cellular uptake activity of the liposomes, the 
cells were stained with NucBlueTM Live ReadyProbesTM 
reagent for 20 min before imaging. The cells were imaged 
using an Olympus FV3000 confocal laser scanning 
microscopy system. A laser source at 405  nm was used 
for the excitation of VP.
For flow cytometry measurements, after incubation 
with the liposome suspension, the cells were washed 
three times with Dulbecco’s phosphate buffered saline, 
trypsinized, centrifuged at 3000  rpm for 3  min, and 
resuspended in DPBS. The cells were then analyzed using 
a flow cytometer (LSRFortessa™ X-20 cell analyser, BD 
Biosciences) equipped with a violet laser. FlowJo software 
was used for further analysis of FCM data.
Intracellular 1O2 detection
HCT116 cells were cultured in glass-bottom petri dishes 
at a concentration of 1 × 105 cells/mL. The cells were 
then treated with different liposome samples (250  µM) 
in culture medium for 3 h at 37 °C, followed by addition 
of SOSG solution (50  µM) for further 1  h incubation). 
After washed with fresh medium, the cells were irradi-
ated with X-rays at different doses. SOSG fluorescence 
signal was imaged under FV3000 confocal laser scanning 
microscope. A laser at 488 nm was used for SOSG excita-
tion. Quantitative analysis of SOSG signal was conducted 
by using ImageJ software, which indicated the intracel-
lular 1O2 level generated under different experimental 
conditions.
Mitochondrial localization of TPP‑conjugated liposomes
HCT116 cells were seeded on a glass-bottom petri dish 
at a concentration of 1 × 105 cells/mL for 48  h. After 
that the cells were incubated with liposome suspen-
sion for 4  h. After being washed two times with PBS, 
the cells were co-stained with Mitotracker Red (0.2 μM) 
and NucBlueTM Live ReadyProbesTM reagent in live 
cell imaging solution at 37 °C for 30 min. The cells were 
then washed twice with PBS and kept in live cell imag-
ing solution for confocal imaging under FV3000 confo-
cal laser scanning microscope. Laser sources at 405  nm 
and 561 nm were used for the capture of nucleus, VP and 
MitoTracker, respectively. Colocalization between TPP-
conjugated liposomes and lysosomes was also verified 
by using LysoTracker™ Red DND-99 (0.2 μM) under the 
same experimental conditions, instead of MitoTracker™ 
Red.
Apoptosis and necrosis assay
The apoptosis and necrosis assays were carried out 
using an apoptosis/necrosis/healthy detection kit. The 
kit allows simultaneous imaging of apoptotic (green), 
necrotic (red) and healthy cells (blue). HCT116 cells 
(1 × 105 cells/mL) were first seeded onto glass-bottom 
petri dishes in the culture medium and then incubated 
with different liposome suspension for 4  h. After being 
washed with fresh medium, the cells were irradiated 
with 4  Gy X-ray and kept incubation for another 48  h. 
The cells were washed twice with PBS and co- stained 
with Hoechst33342, FITC-Annexin V, and Ethidium 
Homodimer III (EthD-III) provided by the kit in binding 
solution (5X dilution) at room temperature for 15 min in 
darkness. Multiple fluorescence images were taken using 
three filters: (1) Hoechst33342 (λabs/λem = 350/461), indi-
cating healthy cells; (2) FITC (λabs/λem = 492/514  nm), 
representing apoptosis, and (3) ethidium homodimer 
λabs/λem = 528/617 nm), indicating necrosis.
Cell viability assays after X‑ray induced PDT
Cells (1 × 104/mL) were seeded onto 96-well plates and 
cultured for 48 h at 37  °C. When the cells reached 70% 
confluency, they were divided into four groups: con-
trol cells without treatment, cells incubated with the 
liposomes alone, cells treated with X-ray alone and cells 
treated with X-ray induced PDT. At 24 h post treatment, 
cellular cytotoxicity was assessed using the Cell Viability 
Assay Kit, MTS (Promega Corporation, USA) according 
to its protocol. The MTS assays were carried out under a 
plate reader (SpectraMax MiniMax 300 Imaging Cytom-
eter, Molecular Devices). Cell viability was calculated as 
a percentage of the absorbance of the untreated control 
cells that was set to 100%.
Assessment on mitochondrial membrane potential (Δψm)
After HCT116 cell seeding, they were respectively incu-
bated with liposome-TPP conjugates and non-conjugated 
liposomes in the cell medium for 4 h, followed by X-ray 
radiation at 4  Gy. At 24  h post treatment, cells were 
stained with 5 µM JC-1 probe at 37 °C for 15 min before 
fluorescence imaging. JC-1 fluorescence signal was cap-
tured at 590 ± 17  nm (red aggregates) and 530 ± 15  nm 
(green monomers), respectively. The Δψm analysis was 
conducted using ImageJ software to calculate the ratio of 
red-to-green channel intensities.
Page 6 of 13Gu et al. J Nanobiotechnol           (2020) 18:87 
Western blotting analysis
HCT116 cells were treated with TPP-conjugated 
liposomes for 4 h, X-rays only or with the combination of 
liposomes and X-ray treatment. After treatments the cells 
were washed twice with PBS and lysed with the RIPA 
buffer supplemented with a protease inhibitor cocktail 
(addition of protease inhibitor to the RIPA buffer imme-
diately before use) according to the manufacturer proto-
col (ThermoFisher Scientific Australia). In Brief, 250 µL 
of the mixture was added to the cell pellet, followed by 
shaking the cell pellet gently for 15 min on ice. The cell 
mixture was centrifuged at ~ 14,000×g for 15  min to 
pellet the cell debris. The supernatant (extracted pro-
teins) was transferred to a new tube for gel running. 
The extracted proteins were loaded in the wells of the 
Bis–Tris protein gel. After separation the proteins were 
transferred to PVDF membranes. The membranes were 
blocked with a blocking buffer (Thermo Fisher Scien-
tific) for 1 h at room temperature and incubated with pri-
mary antibodies against Bax, BAD and cleaved caspase-3 
at 4  °C overnight. All primary antibodies were diluted 
1:1000. After washing with TBST 3 times, the membranes 
were incubated with the corresponding HRP-conjugated 
secondary antibodies for 1  h at room temperature. All 
secondary antibodies were diluted 1:1000. After washing 
with TBST 3 times, the membranes were visualises using 
Western Blotting Substrate on a ChemiDoc™ MP Imag-
ing System (Bio-Rad Laboratories, Inc., USA). Quantifi-
cations of western blots was conducted by using ImageJ 
software.
Statistical analysis
All quantitative data are shown as mean ± SD, n ≥ 3. Sta-
tistical analysis was conducted using GraphPad Prism 
t test calculator and *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001.
Results and discussion
Characterization of liposomes incorporating VP and gold 
nanoparticles
We prepared several types of liposome samples including 
liposomes incorporating VP and gold nanoparticles of 
two sizes 10 nm and 5 nm (Lipo-VP-10Au for 10 nm gold 
Fig. 1 Characterisation of liposomes incorporating VP and gold nanoparticles. a Photograph of liposome samples and pure gold colloidal solution. 
b Absorption spectra of different liposome samples and pure gold colloidal solution. Red arrows indicated typical absorption peaks of VP (~ 410 nm 
and ~ 689 nm), 5 nm gold nanoparticles (~ 515 nm and 10 nm gold nanoparticles ~ 517 nm). c–e TEM images of 10 nm gold nanoparticles (c) pure 
liposomes (d) and liposomes loaded with 10 nm gold nanoparticles (e) Red arrows indicate gold nanoparticles encapsulated inside the liposomes
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and Lipo-VP-5Au for 5 nm gold), liposomes incorporat-
ing VP (Lipo-VP) only and empty liposomes.
The sizes and zeta potential of as-prepared liposomes 
are summarised in Additional file  1: Fig. S1. Figure  1a 
and b shows photographs and the absorption spectra 
of pure gold colloidal solutions and different liposome 
samples. An obvious colour difference was observed 
between the pure gold colloidal solution and liposome-
formulated gold (Fig.  1a). Such colour change from red 
to blue indicates the aggregation of gold nanoparticles 
when they were loaded inside liposomes, which is appar-
ent in the red shift of the gold absorption peak shown in 
Fig. 1b. The absorption peak of 10 nm gold nanoparticles 
shifted from 517 nm in the colloidal solution to 537 nm 
in liposomes indicating some aggregation in the liposo-
mal membranes. The absorption peaks of VP around 
410 nm and 689 nm were observed in both Lipo-VP and 
Lipo-VP-10Au (Fig. 1b), confirming incorporation of VP, 
the peak location is consistent with published work [38]. 
We analysed the absorption spectra of pure TPP, Lipo-
VP and TPP-Lipo-VP as shown Additional file 1: Fig. S1. 
The characteristic absorption peak of pure TPP is around 
267  nm, which is also observed in the TPP-Lipo-VP 
sample.
The TEM image illustrate the morphology of liposomes 
confirming that the 10  nm gold nanoparticles were 
incorporated in the hydrophilic core (Fig. 1e). The TEM 
contrast is provided by higher electron density of gold 
compared with the liposomes. A similar TEM image of 
the liposomes incorporating 5  nm gold nanoparticles is 
shown in Additional file 1: Fig. S2 where gold nanoparti-
cle clusters were observed.
1O2 generation under X‑ray radiation
Generation of cytotoxic ROS, such as 1O2 is a key fac-
tor responsible for the PDT effect. 1O2 generation in this 
work was determined by using the SOSG probe which 
produces a strong fluorescence signal at 525  nm for 
488 nm excitation in the presence of 1O2 [24]. We con-
firmed 1O2 generation by monitoring the SOSG fluo-
rescence intensity at 525  nm wavelength at different 
X-ray doses, as displayed in Fig.  2a. Among the tested 
liposomes loaded with 10  nm and 5  nm gold nanopar-
ticles, those with 10 nm gold (Lipo-VP-10Au) produced 
the highest amount of 1O2, with a percentage increase 
of approximately 186% under X-ray radiation at 4  Gy 
(Fig. 2b). For 5 nm gold loaded samples (Lipo- VP-5Au), 
we observed a 129% increase in 1O2 enhancement, com-
pared with liposomes with only VP (Lipo-VP) (91%). 
Such enhancement of 1O2 in the presence of gold nano-
particles is consistent with our previous work [24] and 
attributed to the following mechanism. As a heavy metal 
element, gold nanoparticles are well-known radiosensi-
tizers, able to amplify the radiation doses in tumour tis-
sue [39, 40]. As a consequence, the VP molecules in the 
presence of gold nanoparticles are able to interact more 
strongly with ionising radiation than the VP on its own, 
causing enhanced 1O2 generation (Fig. 2b).
Intracellular 1O2 generation
After confirmation of 1O2 generation in solution, we 
assessed the intracellular 1O2 generation under different 
treatment conditions (liposomes ± X-ray radiation). As 
shown in Fig. 3a and b, the SOSG fluorescence intensity 
observed in the cells treated with 4  Gy X-ray radiation 
did not show significant differences compared with the 
Fig. 2 1O2 generation from different liposome samples under X-ray radiation. a Relative SOSG fluorescence intensities from liposome samples at 
different X-ray doses. b Percentage increase in SOSG fluorescence intensities from different liposome samples under 4 Gy X-ray radiation. Error bars 
show standard deviation from four measurements
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untreated control cells (p = 0.32). This suggests that the 
dose of 4 Gy is safe for the cells use in this study. A similar 
amount of 1O2 was found in the cell groups respectively 
treated with Lipo-VP, TPP-Lipo-VP and TPP-Lipo-VP-
10Au alone (Fig. 3c, e and g). Also, no significant differ-
ences were observed compared with the control group 
(p = 0.07, 0.11 and 0.07, respectively). This indicates that 
minimal 1O2 was generated by the empty liposomes in 
these conditions.
However, a clearly higher 1O2 production was 
observed in the cells treated with X-ray triggered lipo-
some samples (Fig.  3d, f and h). Among these samples, 
TPP-Lipo–VP-10Au in combination with 4 Gy generated 
the highest amount of 1O2.
In addition, we checked the intracellular 1O2 produc-
tion under varying X-ray radiation dose. As shown in 
Additional file 1: Fig. S3, even under 6 Gy radiation alone, 
the 1O2 generation was still lower than in the cells treated 
with Lipo-VP-10Au in combination with 4 Gy (Fig. 3h). 
All these findings indicate that intracellular 1O2 genera-
tion is induced by the interaction between X-rays and 
a combination of VP and gold nanoparticles have aug-
mented this effect.
Fig. 3 Intracellular 1O2 production from liposomes with and without X-ray radiation. (a–h) Representative confocal laser scanning microscopy 
images of SOSG in a HCT116 cells without any treatment, b HCT116 cells after 4 Gy X-ray irradiation, c HCT116 cells treated with Lipo-VP (250 µM) 
for 4 h, d HCT116 cells treated with Lipo-VP (250 µM) for 4 h and 4 Gy X-ray irradiation, e HCT116 cells treated with TPP-Lipo-VP (250 µM) for 4 h, f 
HCT116 cells treated with TPP-Lipo-VP (250 µM) for 4 h and 4 Gy X-ray irradiation, g HCT116 cells treated with Lipo-VP-10Au (250 µM) for 4 h and h 
HCT116 cells treated with Lipo-VP-10Au (250 µM) for 4 h and 4 Gy X-ray irradiation. Scale bar is 70 µm. g Quantitative analysis of 1O2 generation in 
HCT116 cells at different treatment conditions
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Mitochondria localization of TPP‑conjugated liposomes
Mitochondria have been proposed to be the most effec-
tive subcellular targets in PDT since ROS-induced 
mitochondrial DNA damage results in augmented cyto-
toxicity in PDT [9]. Therefore, it would be desirable for 
photosensitisers or their delivery vehicles to be accumu-
lated within or in close proximity to mitochondria. To 
achieve this, we conjugated the liposomes with a mito-
chondria-targeting moiety, TPP using the EDC-NHS 
coupling method. The mitochondria-targeting capabili-
ties of the TPP-Lipo-VP were investigated by incubating 
the targeted liposomes loaded with VP alone (TPP-Lipo-
VP) with HCT116 cells and using non-targeted Lipo-VP 
as controls.
As shown in Fig.  4a and b, cells treated with TPP-
Lipo-VP showed a higher liposomal uptake than non-
conjugated liposomes Lipo-VP in the mitochondria. In 
this figure we are relying on intrinsic fluorescence of VP. 
Quantitative analysis using the ImageJ/Fiji “colocalization 
analysis” function also revealed a higher degree of over-
lap of the TPP-conjugated liposomes with MitoTracker 
in the mitochondria of the cells (Pearson’s correlation 
coefficient, PCC = 0.63), compared with the non-con-
jugated liposomes (PCC = 0.53). This indicated that the 
TPP-conjugated liposomes have a greater mitochondrial 
selectivity than non-targeted ones. In addition, TPP-
Lipo-VP showed almost no colocalization with the lys-
osomes labelled by Lysotracker (PCC = − 0.03, Fig.  4c), 
indicating these TPP-modified liposomes were, in fact, 
preferentially accumulated in mitochondria due to the 
capability of TPP for mitochondrial targeting. These find-
ings are consistent with other reports on the localization 
of TPP-modified nanoparticles to the mitochondria of 
pancreatic cancer, endothelial, and prostate cancer cells 
[41, 42].
Based on these data we selected TPP-conjugated 
liposomes as the therapeutic agent for further studies. 
We investigated the cellular uptake of TPP-Lipo-VP in 
the HCT116 cells by incubating the cells with TPP-Lipo-
VP for 1 h, 2 h and 4 h, respectively. As shown in Addi-
tional file  1: Fig. S4a, the pseudo green colour from VP 
was clearly observed after 2  h and 4  h incubation time, 
compared with 1  h confirming cellular uptake of TPP-
Lipo-VP which appears to reach saturation after 2  h 
treatment. Consistently, we found no significant differ-
ence in VP fluorescence intensity between 2  h and 4  h 
incubation via flow cytometry measurements (Additional 
file 1: Fig. S4b), therefore we chose 2 h incubation time 
for further cellular experiments.
Alterations in the mitochondrial membrane potential
To verify whether the mitochondrial function was 
affected by X-ray induced PDT using our liposomes, the 
mitochondrial membrane potential was examined by 
JC-1 staining and confocal microscopy. The JC-1 probe 
was used to evaluate the changes in Δψm upon liposome 
administration. The JC-1 dye is aggregated in normal 
mitochondrial membrane causing the dye to emit red 
fluorescence. By contrast, in the unhealthy or damaged 
mitochondria JC-1 monomers localise in the membrane 
at low concentrations, producing green fluorescence. 
Thus, the ratio of JC-1 aggregates (red signal) to mono-
mers fluorescence (green signal) can be used as an indi-
cator to analyse Δψm. As shown in Fig.  5a, c and e, the 
JC-1 signal was not obviously changed in the cells treated 
with liposomes (TPP-Lipo-VP or TPP-Lipo-VP-10Au), 
compared with the control group. This indicates mini-
mal toxicity of the liposomes in HCT116 cells under the 
experimental conditions. However, when we combined 
the aforementioned liposomes with X-ray radiation, the 
cells presented a weaker red signal due to mitochondrial 
depolarization induced by the cytotoxic singlet oxygen 
generated by the X-ray induced PDT effect (Fig. 5d and 
f ). In particular, the cells treated with TPP-conjugated 
liposomes exposed to X-rays exhibited the largest Δψm 
damage (the smallest red/green ratio in Fig.  5g), which 
was consistent with our previous data for the intracellu-
lar 1O2 production (Fig. 3f ).
Fig. 4 Colocalization of Lipo-VP and TPP-Lipo-VP with the 
mitochondria and lysosomes. a–c Representative confocal laser 
scanning microscopy images of VP (pseudo green colour to 
distinguish between VP and trackers), Mitotracker Red (red channel) 
and LysoTracker (red channel) in HCT116 cells after incubation with 
Lipo-VP (250 µM) and TPP-Lipo-VP (250 µM). Merged images of green 
and red channels indicated colocalization level of the liposomes and 
mitochondria (or lysosomes). Scale bar is 20 µm
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In vitro cytotoxicity
We further assessed the cytotoxicity of the in  vitro 
X-ray induced PDT effect in HCT116 cells. Cell 
viability assays under various treatments were 
performed to estimate the potential cytotoxic-
ity effect on HCT116 by using the MTS assay. Both 
Fig. 5 Changes in JC-1 fluorescence signal (Δψm) in HCT116 cells under different treatment conditions: a the cells without any treatment, b the 
cells treated with 4 Gy X-ray radiation, c the cells treated with TPP-Lipo-VP (250 µM), d the cells treated with TPP-Lipo-VP (250 µM) and 4 Gy X-ray 
radiation, e the cells treated with TPP-Lipo-VP-10Au (250 µM) and f the cells treated with TPP-Lipo-VP-10Au (250 µM) and 4 Gy X-ray radiation. Scale 
bar is 20 µm. The high-membrane potential resulted in the JC-1 aggregation in the membrane, as shown by the strong red fluorescent signal, and 
low membrane potential caused the monodispersed release of JC-1 to the cytosol, as shown by the strong green fluorescent signal. g Red-to-green 
channel ratio determines the rate of membrane potential decay and cells dead
Fig. 6 a In vitro cytotoxicity of TPP-Lipo-VP-10Au in HCT116 cells after X-ray irradiation. The cells were treated with X-ray alone, TPP-Lipo-VP-10Au 
(250 µM) alone and combined condition. b The dark cytotoxicity of TPP-Lipo-VP-10Au (250 µM) and X-ray irradiation (4 Gy) in CCD841 CoN cells
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TPP-Lipo-VP-10Au (p = 0.4972) and the X-ray radia-
tion alone (p = 0.1334) induced low cytotoxicity 
in HCT116 cells and normal colon CCD 841 cells 
(p = 0.7342), with minimal changes to cell viabil-
ity compared to the control group (Fig.  6). However, 
when these two treatments were combined, a signifi-
cant decrease in HCT116 cell survival was observed 
(49.8%). This enhanced cytotoxicity effect is attributed 
to efficient production of 1O2 from the activated VP 
under X-ray radiation augmented by ROS generation 
by gold nanoparticles under these conditions.
In vitro X‑ray induced PDT effect and apoptosis/necrosis 
assays
The apoptosis/necrosis assays were also carried out to 
investigate the cell death pathways under our treatment 
conditions. Under X-ray radiation alone and TPP-Lipo-
VP-10Au alone, the cells showed a low-level apoptosis 
and necrosis, compared with the controls (Fig. 7a, b and 
c). This indicated that the lethality of low dose X-ray and 
the liposomes with the current concentration is negligi-
ble. By contrast, after the treatment with TPP-Lipo-VP-
10Au and 4 Gy, the percentage of apoptotic and necrotic 
cells significantly increased to about 26% and 19%, 
respectively. Correspondingly, the percentage of healthy 
cells reduced from 99% in the control to 55% in the cells 
treated with (Fig. 7d). Taken together, these findings indi-
cate that mitochondria-targeted liposomes displayed the 
higher in vitro X-ray induced PDT effect. To further elu-
cidate the mechanism of PDT-mediated apoptosis, we 
investigated the expression of apoptosis-related proteins 
in HCT116 cells using western blotting. Bax and BAD 
regulate apoptosis mainly at the level of the mitochondria 
[43]. Caspase is also an important apoptosis inducer that 
exists on the outer membranes of mitochondria [44]. As 
shown in Fig.  7f, increased expression of Bax and BAD 
as well as activated caspase-3 was observed in the cells 
treated with TPP-conjugated liposomes in combina-
tion with 4  Gy radiation, indicating that X-ray induced 
PDT led to cell apoptosis mainly via the mitochondrial 
pathways.
Conclusions
We have developed a novel mitochondrially-targeted 
liposome delivery system for an enhanced X-ray PDT 
effect in deep tissue. The liposomes were formulated by 
Fig. 7 Apoptosis/necrosis assays performed in HCT116 cells at 24 h after the treatments. a–d Representative confocal laser scanning microscopy 
images of the cells after different treatments as indicated. The concentration of TPP-Lipo-VP-10Au used to treat the cells was 250 µM. Scale bar 
is 70 µm. e Relative changes in levels of apoptosis and necrosis upon different treatments as indicated in a–d. f Relative protein expression was 
analysed by using ImageJ software. Protein expression was normalized by use of the loading control protein (β-actin)
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co-embedding VP and gold nanoparticles in the same 
liposomal platform and then they were conjugated with 
TPP to target mitochondria. These liposomes exhibited 
a mitochondria-targeting capacity and they enhanced 
1O2 generation in HCT116 cells under X-ray radiation at 
4  Gy. We have also observed X-ray PDT-induced mito-
chondrial damage and elucidated the mechanisms of 
cancer cell death. Together, these results show the mito-
chondria-targeted and X-ray triggerable liposome deliv-
ery system could provide new options beyond traditional 
PDT for deep tumour therapy.
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